# Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

> **NCT04572451** · PHASE1 · RECRUITING · sponsor: **Yana Najjar** · enrollment: 50 (estimated)

## Conditions studied

- Melanoma
- Unresectable Solid Tumors
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms by Site
- Antineoplastic Agents, Immunological
- Antineoplastic Agents
- Immune Checkpoint Inhibitors
- Molecular Mechanisms of Pharmacological Action
- Nivolumab

## Interventions

- **DRUG:** nivolumab
- **DRUG:** BMS-986253
- **RADIATION:** Stereotactic Body Radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT04572451
- **Lead sponsor:** Yana Najjar
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-29
- **Primary completion:** 2024-05-17
- **Final completion:** 2027-05-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04572451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04572451, "Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04572451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*